Pegloticase therapy improves physical function and health-related quality of life in patients with refractory chronic gout, according to this analysis of patient-reported-outcome data. At week 25, patients who received 8 mg pegloticase biweekly (n = 85) showed significant, clinically meaningful improvements in patient global assessment of disease activity, pain, Health Assessment Questionnaire Disability Index and physical component summary scores, whereas patients who received placebo did not (n = 43).
ORIGINAL RESEARCH PAPER
Strand, V. et al. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J. Rheumatol. doi:10.3899/jrheum.111375
Rights and permissions
About this article
Cite this article
Pegloticase therapy improves quality of life. Nat Rev Rheumatol 8, 438 (2012). https://doi.org/10.1038/nrrheum.2012.105
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.105